ANIX Insider Trading

Insider Ownership Percentage: 25.30%
Insider Buying (Last 12 Months): $412,198.89
Insider Selling (Last 12 Months): $0.00

Anixa Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Anixa Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$177kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k$0$100kTotal Insider BuyingTotal Insider Selling

Anixa Biosciences Share Price & Price History

Current Price: $2.97
Price Change: Price Decrease of -0.11 (-3.57%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for ANIX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$2.97Closing price on 03/29/25:

SEC Filings (Institutional Ownership Changes) for Anixa Biosciences (NASDAQ:ANIX)

29.13% of Anixa Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ANIX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$471kbought$286ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M$0$1MTotal InflowsTotal Outflows
Anixa Biosciences logo
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Read More on Anixa Biosciences

Today's Range

Now: $2.97
Low: $2.83
High: $3.08

50 Day Range

MA: $2.97
Low: $2.41
High: $3.20

52 Week Range

Now: $2.97
Low: $2.07
High: $4.20

Volume

81,233 shs

Average Volume

97,441 shs

Market Capitalization

$95.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Who are the company insiders with the largest holdings of Anixa Biosciences?

Anixa Biosciences' top insider investors include:
  1. Lewis H Titterton Jr (Director)
  2. Amit Kumar (CEO)
  3. Arnold M Baskies (Director)
  4. Michael Catelani (CFO)
Learn More about top insider investors at Anixa Biosciences.

Who are the major institutional investors of Anixa Biosciences?

Anixa Biosciences' top institutional shareholders include:
  1. Mission Wealth Management LP — 1.46%
  2. Bank of America Corp DE — 0.65%
  3. Long Focus Capital Management LLC — 0.46%
  4. Focus Partners Wealth — 0.22%
  5. Northern Trust Corp — 0.21%
  6. LPL Financial LLC — 0.13%
Learn More about top institutional investors of Anixa Biosciences stock.

Which major investors are selling Anixa Biosciences stock?

During the last quarter, ANIX stock was sold by these institutional investors:
  1. Mission Wealth Management LP
  2. International Assets Investment Management LLC
  3. Long Focus Capital Management LLC
  4. Bank of America Corp DE
  5. Northern Trust Corp

Which major investors are buying Anixa Biosciences stock?

In the previous quarter, ANIX stock was acquired by institutional investors including:
  1. Focus Partners Wealth
  2. Jane Street Group LLC
  3. Prosperity Wealth Management Inc.
  4. LPL Financial LLC
  5. Millennium Management LLC
  6. Citadel Advisors LLC
  7. Renaissance Technologies LLC
In the last year, these company insiders have bought Anixa Biosciences stock:
  1. Lewis H Titterton Jr (Director)
  2. Amit Kumar (CEO)
  3. Arnold M Baskies (Director)
  4. Michael Catelani (CFO)
Learn More investors buying Anixa Biosciences stock.